267 related articles for article (PubMed ID: 28470787)
1. The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease.
Ananthakrishnan AN; Sakuraba A; Barnes EL; Pekow J; Raffals L; Long MD; Sandler RS
Aliment Pharmacol Ther; 2017 Jul; 46(2):162-168. PubMed ID: 28470787
[TBL] [Abstract][Full Text] [Related]
2. Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study.
Murthy SK; Begum J; Benchimol EI; Bernstein CN; Kaplan GG; McCurdy JD; Singh H; Targownik L; Taljaard M
Gut; 2020 Feb; 69(2):274-282. PubMed ID: 31196874
[TBL] [Abstract][Full Text] [Related]
3. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study.
Targownik LE; Benchimol EI; Bernstein CN; Singh H; Lix L; Tennakoon A; Leung S; Aviña A; Coward S; Jones J; Kaplan G; Murthy SK; Nguyen GC; Peña-Sánchez JN
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1788-1798.e2. PubMed ID: 30448599
[TBL] [Abstract][Full Text] [Related]
4. Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications.
Targownik LE; Benchimol EI; Bernstein CN; Singh H; Tennakoon A; Zubieta AA; Coward S; Jones J; Kaplan GG; Kuenzig ME; Murthy SK; Nguyen GC; Peña-Sánchez JN
J Crohns Colitis; 2020 Oct; 14(10):1354-1363. PubMed ID: 32648579
[TBL] [Abstract][Full Text] [Related]
5. Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease.
Lindsay JO; Armuzzi A; Gisbert JP; Bokemeyer B; Peyrin-Biroulet L; Nguyen GC; Smyth M; Patel H
Dig Liver Dis; 2017 Oct; 49(10):1086-1091. PubMed ID: 28826571
[TBL] [Abstract][Full Text] [Related]
6. Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents.
Guasch M; Cañete F; Ordás I; Iglesias-Flores E; Clos A; Gisbert JP; Taxonera C; Vera I; Mínguez M; Guardiola J; Rivero M; Nos P; Gomollón F; Barrio J; de Francisco R; López-Sanromán A; Martín-Arranz MD; Garcia-Planella E; Camargo R; García-López S; de Castro L; Calvet X; Esteve M; Mañosa M; Domènech E;
J Gastroenterol Hepatol; 2020 Dec; 35(12):2080-2087. PubMed ID: 32350906
[TBL] [Abstract][Full Text] [Related]
7. An Increased Serum N-Terminal Telopeptide of Type I Collagen, a Biochemical Marker of Increased Bone Resorption, Is Associated with Infliximab Therapy in Patients with Crohn's Disease.
Sugimoto K; Ikeya K; Iida T; Kawasaki S; Arai O; Umehara K; Watanabe F; Tani S; Oishi S; Osawa S; Yamamoto T; Hanai H
Dig Dis Sci; 2016 Jan; 61(1):99-106. PubMed ID: 26254083
[TBL] [Abstract][Full Text] [Related]
8. Visceral adiposity and inflammatory bowel disease.
Rowan CR; McManus J; Boland K; O'Toole A
Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
[TBL] [Abstract][Full Text] [Related]
9. Stricturing and Fistulizing Crohn's Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease.
Weizman AV; Sharma R; Afzal NM; Xu W; Walsh S; Stempak JM; Nguyen GC; Croitoru K; Steinhart AH; Silverberg MS
Dig Dis Sci; 2018 Sep; 63(9):2430-2438. PubMed ID: 29736839
[TBL] [Abstract][Full Text] [Related]
10. Factors predicting the therapeutic response to infliximab during maintenance therapy in Japanese patients with Crohn's disease.
Matsuoka K; Hamada S; Shimizu M; Nanki K; Mizuno S; Kiyohara H; Arai M; Sugimoto S; Iwao Y; Ogata H; Hisamatsu T; Naganuma M; Kanai T; Mochizuki M; Hashiguchi M
PLoS One; 2018; 13(10):e0204632. PubMed ID: 30286108
[TBL] [Abstract][Full Text] [Related]
11. Exploring treatment of inflammatory bowel disease with infliximab in the Middle East and Northern Africa: An analysis of the HARIR observational cohort study.
Alharbi O; Hamed W; Salem O; Taylor C; Besar A; Sharaf M
Saudi J Gastroenterol; 2023; 29(3):164-170. PubMed ID: 37313946
[TBL] [Abstract][Full Text] [Related]
12. Sequential Combination Therapy Versus Monotherapy: A Lack of Benefit in Time to Inflammatory Bowel Disease-Related Surgery.
Barnes EL; Goldin A; Winter RW; Collins E; Cao B; Carrellas M; Crowell AM; Korzenik JR
Dig Dis Sci; 2016 Nov; 61(11):3261-3269. PubMed ID: 27639871
[TBL] [Abstract][Full Text] [Related]
13. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
Chaparro M; Barreiro-de Acosta M; Echarri A; Almendros R; Barrio J; Llao J; Gomollón F; Vera M; Cabriada JL; Guardiola J; Guerra I; Beltrán B; Roncero O; Busquets D; Taxonera C; Calvet X; Ferreiro-Iglesias R; Ollero Pena V; Bernardo D; Donday MG; Garre A; Godino A; Díaz A; Gisbert JP
Dig Dis Sci; 2019 Mar; 64(3):846-854. PubMed ID: 30426297
[TBL] [Abstract][Full Text] [Related]
14. Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease.
Boyapati RK; Torres J; Palmela C; Parker CE; Silverberg OM; Upadhyaya SD; Nguyen TM; Colombel JF
Cochrane Database Syst Rev; 2018 May; 5(5):CD012540. PubMed ID: 29756637
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials.
Ben-Horin S; Novack L; Mao R; Guo J; Zhao Y; Sergienko R; Zhang J; Kobayashi T; Hibi T; Chowers Y; Peyrin-Biroulet L; Colombel JF; Kaplan GG; Chen MH
Gastroenterology; 2022 Feb; 162(2):482-494. PubMed ID: 34757139
[TBL] [Abstract][Full Text] [Related]
16. Influence of polymorphisms and TNF and IL1β serum concentration on the infliximab response in Crohn's disease and ulcerative colitis.
Lacruz-Guzmán D; Torres-Moreno D; Pedrero F; Romero-Cara P; García-Tercero I; Trujillo-Santos J; Conesa-Zamora P
Eur J Clin Pharmacol; 2013 Mar; 69(3):431-8. PubMed ID: 22960943
[TBL] [Abstract][Full Text] [Related]
17. Comparative Effectiveness of Infliximab and Adalimumab in Crohn's Disease and Ulcerative Colitis.
Ananthakrishnan AN; Cagan A; Cai T; Gainer VS; Shaw SY; Savova G; Churchill S; Karlson EW; Kohane I; Liao KP; Murphy SN
Inflamm Bowel Dis; 2016 Apr; 22(4):880-5. PubMed ID: 26933751
[TBL] [Abstract][Full Text] [Related]
18. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation.
Bortlik M; Duricova D; Machkova N; Hruba V; Lukas M; Mitrova K; Romanko I; Bina V; Malickova K; Kolar M; Lukas M
Scand J Gastroenterol; 2016; 51(2):196-202. PubMed ID: 26329773
[TBL] [Abstract][Full Text] [Related]
19. Dual therapy with infliximab and immunomodulator reduces one-year rates of hospitalization and surgery among veterans with inflammatory bowel disease.
Abraham NS; Richardson P; Castillo D; Kane SV
Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1281-7. PubMed ID: 23792295
[TBL] [Abstract][Full Text] [Related]
20. Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study.
Jung YS; Han M; Park S; Cheon JH
Dig Dis Sci; 2020 May; 65(5):1436-1444. PubMed ID: 31677070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
